Evaluating the impact of novel inhibitors of nuclear pore export in SLE
Ended Project Grant Awarded Last action
- Award ID
- R44AI124949
- Recipient
-
Karyopharm Therapeutics Inc. UEI JF64YMCE9V63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,974,922
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $982,411 | |
| Original award | $992,511 |
Quick answers
Who received award R44AI124949?
R44AI124949 was awarded to Karyopharm Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2016.
How much is award R44AI124949 worth?
$1,974,922 has been obligated on R44AI124949.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award